Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report

BACKGROUND: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab is a low-density lipoprotein (LDL)-lowering drug with a new mechanism, which is currently available in Japan. Here, for the first time, we report the successful use of the PCSK9 inhibitor in a patient with ref...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:BMC Nephrol
Prif Awduron: Awanami, Yuki, Fukuda, Makoto, Nonaka, Yasunori, Takashima, Tsuyoshi, Matsumoto, Keiichiro, Yamasaki, Masatora, Miyazono, Motoaki, Ikeda, Yuji
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2017
Pynciau:
Case Report
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5501341/
https://ncbi.nlm.nih.gov/pubmed/28683788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12882-017-0644-0
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg